ArticleFrontiers in immunology2026
Case Report: a three-stage treatment strategy combining immunotherapy with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal squamous cell carcinoma (ESCC), a common malignant tumor with high incidence and mortality in China, remains challenging to treat, especially in advanced stages. Traditional definitive chemoradiotherapy (dCRT) has been the standard care for unresectable locally advanced ESCC but has shown limited long-term efficacy. Recent advances in immune checkpoint inhibitors (ICIs) have opened new avenues for enhancing treatment outcomes. This case report details a 62-year-old male with upper thoracic LA-ESCC (cT3N1M0) who underwent a comprehensive three-stage treatment strategy combining immunotherapy with dCRT. The treatment phases included induction chemotherapy with immunotherapy, followed by radical chemoradiotherapy, and subsequent immunotherapy maintenance. The patient demonstrated significant tumor regression, achieving a complete response and a progression-free survival of 27 months by December 13, 2025. During the treatment, immune-related adverse events (irAEs), including immune diabetes, emerged but were managed effectively through timely intervention and monitoring. This report underscores the potential of immunotherapy combined with dCRT to enhance survival and quality of life in patients with unresectable LA-ESCC. It also identifies key areas for further research: optimizing treatment protocols, improving management of immune-related adverse events, and identifying predictive biomarkers for treatment response. Large-scale prospective clinical trials will be essential to refine these strategies and advance precision therapy in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.